US Stock MarketDetailed Quotes

SNDX Syndax Pharmaceuticals

Watchlist

18.890
+0.730+4.02%

Close Sep 27 16:00 ET

18.890
0.0000.00%

Post 16:09 ET

1.61BMarket Cap-5555P/E (TTM)

Syndax Pharmaceuticals Stock Forum

Meltyy

Aug 21 02:00

FDA PDUFA Update…

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

Trytosaveabit

Aug 14 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)

Meltyy

Aug 6 02:59

📅 FDA PDUFA Update…

🚨 This Week’s PDUFA:
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...

Trytosaveabit

Aug 1 13:03

Update

$Syndax Pharmaceuticals (SNDX.US)$ Syndax's revumenib granted FDA orphan drug designation for leukemia

Trytosaveabit

Jul 29 06:16

Update!

$Syndax Pharmaceuticals (SNDX.US)$ FDA announces they need more time? New Pdufa Action Date of December 26, 2024 Allows FDA Additional Time to Complete Their Review! No longer September 26, 2024!

Trytosaveabit

Mar 26 15:51

Update

$Syndax Pharmaceuticals (SNDX.US)$ Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of S...

Moomoo AI

Mar 3 09:07

Syndax Pharmaceuticals' excess liquidity indicates a cautious approach to debt, but its lack of significant operating revenue and EBIT loss over the last year are worrying. The company's balance sheet appears liquid, but the absence of regular free cash flow generation is concerning.

Does Syndax Pharmaceuticals (NASDAQ:SNDX) Have A Healthy Balance Sheet?

Trytosaveabit

Oct 24, 2023 06:05

Update

$Syndax Pharmaceuticals (SNDX.US)$ Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
3 MINUTES AGO, 7:00 AM EDT
VIA PR NEWSWIRE

Trytosaveabit

Oct 11, 2023 12:45

Watching!

$Syndax Pharmaceuticals (SNDX.US)$ See a lot of potential here? with price action after trial PR, its like everyone read ( trial stopped early ) but didn’t read any further? it was stopped for efficacy, it showed improvement and are moving on to next phase!

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data